Adaptive bolus calculators for people with type 1 diabetes: A systematic review
Unsworth R, Avari P, Lett AM, et al.
Diabetes Obes Metab. Pub. online 24 Jul 2023.
Leggi
Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Park S, Jeong HE, Bea S, et al.
Diabetes Obes Metab. Pub. online 28 Jul 2023.
Leggi
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves JS, Borges-Canha M, Vasques-Nóvoa F, et al.
J Am Coll Cardiol. 2023;82 (6) 517–525.
Leggi
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan WN, Sheth KN, et al.
Stroke. 2023;54(8):2013-2021.
Leggi
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Xie Y, Bowe B, Xian H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00171-7.
Leggi
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
Alhiary R, Kesselheim AS, Gabriele S, et al.
JAMA. Pub. online 28 Jul 2023.
Leggi
Nuovi Annali AMD 2022
Carissimi Soci, siamo lieti di condividere i nuovi volumi Annali AMD 2022 – “Valutazione degli indicatori AMD di qualità dell’assistenza al diabete in Italia” - “Diabete tipo 1” e ” Diabete tipo 2”. Siamo giunti alla 12ma edizione di questa iniziativa AMD che ha precorso i tempi in diabetologia contribuendo…
Leggi
